EHA 2018 | Preclinical data for quizartinib plus MDM2 inhibitor in AML
Clinical trials have demonstrated the positive response rates for FLT3 inhibitors like quizartinib in relapsed FLT3-mutated acute myeloid leukemia (AML). A major problem for quizartinib monotherapy, however, is that the durability of the response is quite low, meaning that without stem cell transplants, patients are likely to relapse quickly. In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, discusses preclinical data which show that response durability is increased significantly when quizartinib is combined with the MDM2 inhibitor milademetan. He explores the implications of these findings, and gives an overview of the upcoming Phase I/II trial which is to follow on from these data.
Get great new content delivered to your inboxSign up